HRP20131070T1 - Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima - Google Patents

Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima Download PDF

Info

Publication number
HRP20131070T1
HRP20131070T1 HRP20131070AT HRP20131070T HRP20131070T1 HR P20131070 T1 HRP20131070 T1 HR P20131070T1 HR P20131070A T HRP20131070A T HR P20131070AT HR P20131070 T HRP20131070 T HR P20131070T HR P20131070 T1 HRP20131070 T1 HR P20131070T1
Authority
HR
Croatia
Prior art keywords
allopurinol
medicine
treatment
use according
hands
Prior art date
Application number
HRP20131070AT
Other languages
English (en)
Croatian (hr)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma, S.L.
Advancell Advanced In Vitro Cell Technologies, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobera Pharma, S.L., Advancell Advanced In Vitro Cell Technologies, S.A. filed Critical Nobera Pharma, S.L.
Publication of HRP20131070T1 publication Critical patent/HRP20131070T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20131070AT 2009-04-29 2010-04-29 Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima HRP20131070T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
HRP20131070T1 true HRP20131070T1 (hr) 2013-12-20

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131070AT HRP20131070T1 (hr) 2009-04-29 2010-04-29 Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima

Country Status (22)

Country Link
US (2) US8623878B2 (https=)
EP (2) EP2246057A1 (https=)
JP (1) JP6007101B2 (https=)
KR (1) KR20120049848A (https=)
CN (1) CN102421436B (https=)
AR (1) AR076505A1 (https=)
AU (2) AU2010243594A1 (https=)
BR (1) BRPI1011971A2 (https=)
CA (1) CA2759085C (https=)
DK (1) DK2424538T3 (https=)
ES (1) ES2434366T3 (https=)
HR (1) HRP20131070T1 (https=)
IL (1) IL215831A (https=)
ME (1) ME01567B (https=)
MX (1) MX2011011529A (https=)
NZ (1) NZ595901A (https=)
PL (1) PL2424538T3 (https=)
PT (1) PT2424538E (https=)
RS (1) RS53005B (https=)
RU (1) RU2543325C2 (https=)
SI (1) SI2424538T1 (https=)
WO (1) WO2010125143A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko) * 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
KR20240159565A (ko) 2022-01-05 2024-11-05 아시메트릭 테라퓨틱스, 엘엘씨 피부 증식성 장애 및 다른 피부 병태 치료를 위한 방법 및 조성물
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE66147T1 (de) * 1987-02-13 1991-08-15 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
WO1994005293A1 (en) 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1609468A3 (en) * 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148910A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Apparatus having a skin-contactable element containing an agent
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1791535B1 (en) 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators
WO2007138103A1 (en) 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Also Published As

Publication number Publication date
EP2424538A1 (en) 2012-03-07
HK1168042A1 (en) 2012-12-21
JP6007101B2 (ja) 2016-10-12
CA2759085C (en) 2016-08-16
ME01567B (me) 2014-04-20
ES2434366T3 (es) 2013-12-16
IL215831A0 (en) 2012-01-31
EP2424538B1 (en) 2013-08-14
RS53005B (sr) 2014-04-30
KR20120049848A (ko) 2012-05-17
RU2011148355A (ru) 2013-06-10
CA2759085A1 (en) 2010-11-04
RU2543325C2 (ru) 2015-02-27
US20140080845A1 (en) 2014-03-20
CN102421436A (zh) 2012-04-18
NZ595901A (en) 2013-11-29
US20100280051A1 (en) 2010-11-04
BRPI1011971A2 (pt) 2016-04-26
AR076505A1 (es) 2011-06-15
WO2010125143A1 (en) 2010-11-04
IL215831A (en) 2016-02-29
DK2424538T3 (da) 2013-11-04
AU2010243594A1 (en) 2011-11-10
JP2012525358A (ja) 2012-10-22
US8623878B2 (en) 2014-01-07
SI2424538T1 (sl) 2013-12-31
PL2424538T3 (pl) 2014-05-30
CN102421436B (zh) 2014-05-07
AU2016228193A1 (en) 2016-11-03
PT2424538E (pt) 2013-11-07
EP2246057A1 (en) 2010-11-03
MX2011011529A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
HRP20131070T1 (hr) Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima
ECSP24034690A (es) Formulación tópica para un inhibidor de jak
PH12016501342B1 (en) Intranasal pharmaceutical dosage forms comprising naloxone
BR112014003499A2 (pt) compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
IL186544A (en) Use of Acid 3,1 - Propandysulfonic or Sodium Salt in the Preparation of Pharmaceuticals for the Treatment of aa Amyloidosis and Pharmaceuticals for the Treatment of aa Amyloidosis
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos
CA2736751A1 (en) Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
BR112013012100A2 (pt) composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2010136035A3 (en) Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
JP2013528627A5 (https=)
PL2640364T3 (pl) Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych
GR1006148B (el) Αναβραζοντα δισκια και αναβραζοντα κοκκια που περιεχουν τρυγικη καρνιτινη
BR112015004471A8 (pt) formulação em comprimido de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio
Fernández Martínez Prevalence, impact and treatment of primary dysmenorrhea in workers of an academic and research institute.
MX390789B (es) Composición farmacéutica de dosis fija que comprende mometasona y azelastina.
JP2012072106A5 (https=)
BR112015017541A2 (pt) fármaco profilático ou terapêutico para constipação
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии